# US 2014/0273215 A1 · Methods and compositions for targeted release of molecules from nanoscale carriers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0273215 A1
- Document ID: US20140273215A1
- Status: Published application
- Kind: A1
- Application number: 14/213,148
- Filed: 2014-03-14
- Published: 2014-09-18
- Earliest claimed: 2013-03-14
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: Ting GUO; Zane B. STARKEWOLFE
- Web page: https://patentgrep.com/patent/US20140273215A1

## CPC

- A61K 41/0042: {Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion}
- A61K 47/6923: {the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb}
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES

## Abstract

The present disclosure relates generally to the field of nanoscale materials, and more specifically to the field of nanoscale materials for activating delivered molecules at a target location.

## Claims

### Claim 1

A nanoparticle-based method of providing a treatment to a target cell, the method comprising:
(a) contacting the target cell with a nanomaterial composition, the nanomaterial composition comprising a nanoparticle linked, via a linker, to a therapeutic molecule, and
(b) cleaving the link between the nanoparticle and the therapeutic molecule with irradiation energy to produce a liberated therapeutic molecule,
wherein the biological activity of the liberated therapeutic molecule is greater than the biological activity of the nanomaterial composition.

### Claim 2 (depends on 1)

The method of claim 1, wherein the nanomaterial composition further comprises a drug base scaffold wherein the drug base scaffold is attached to the linker and the drug base scaffold is attached to the therapeutic molecule.

### Claim 3 (depends on 2)

The method of claim 2, wherein the drug base scaffold is a DNA molecule.

### Claim 4 (depends on 1)

The method of claim 1, wherein the nanoparticle comprises a core comprising a metal.

### Claim 5 (depends on 4)

The method of claim 4, wherein the metal is Au.

### Claim 6 (depends on 1)

The method of claim 1, wherein the nanoparticle comprises a shell comprising silica.

### Claim 7 (depends on 6)

The method of claim 6, wherein the shell has attached, at its surface, PEG ligands.

### Claim 8 (depends on 6)

The method of claim 6, wherein the shell has attached, at its surface, targeting moieties.

### Claim 9 (depends on 1)

The method of claim 1, wherein the linker is a DNA molecule.

### Claim 10 (depends on 1)

The method of claim 1, wherein the therapeutic molecule is doxorubicin.

### Claim 11 (depends on 1)

The method of claim 1, wherein the irradiation energy is X-rays.

### Claim 12 (depends on 1)

The method of claim 1, wherein the target cell is a cancer cell.

### Claim 13

A nanoparticle-based method of providing a treatment to a living system, the method comprising:
(a) administering to the living system a nanomaterial composition, the nanomaterial composition comprising a nanoparticle linked, via a linker, to a therapeutic molecule, and
(b) irradiating the living system with irradiation energy sufficient to cleave the link between the nanoparticle and the therapeutic molecule to produce a liberated therapeutic molecule,
wherein the biological activity of the liberated therapeutic molecule is greater than the biological activity of the nanomaterial composition.

### Claim 14 (depends on 13)

The method of claim 13, wherein the nanomaterial composition further comprises a drug base scaffold wherein the drug base scaffold is attached to the linker and the drug base scaffold is attached to the therapeutic molecule.

### Claim 15 (depends on 14)

The method of claim 14, wherein the drug base scaffold is a DNA molecule.

### Claim 16 (depends on 13)

The method of claim 13, wherein the nanoparticle comprises a core comprising a metal.

### Claim 17 (depends on 16)

The method of claim 16, wherein the metal is Au.

### Claim 18 (depends on 13)

The method of claim 13, wherein the nanoparticle comprises a shell comprising silica.

### Claim 19 (depends on 18)

The method of claim 18, wherein the shell has attached, at its surface, PEG ligands.

### Claim 20 (depends on 18)

The method of claim 18, wherein the shell has attached, at its surface, targeting moieties.

### Claim 21 (depends on 13)

The method of claim 13, wherein the linker is a DNA molecule.

### Claim 22 (depends on 13)

The method of claim 13, wherein the therapeutic molecule is doxorubicin.

### Claim 23 (depends on 13)

The method of claim 13, wherein the irradiation energy is X-rays.

### Claim 24 (depends on 13)

The method of claim 13, wherein the living system comprises a cancer cell.

### Claim 25

A nanomaterial composition comprising a nanoparticle linked, via a linker, to a therapeutic molecule.

### Claim 26 (depends on 25)

The composition of claim 25, wherein the nanomaterial composition further comprises a drug base scaffold wherein the drug base scaffold is attached to the linker and the drug base scaffold is attached to the therapeutic molecule.

### Claim 27 (depends on 26)

The composition of claim 26, wherein the drug base scaffold is a DNA molecule.

### Claim 28 (depends on 25)

The composition of claim 25, wherein the nanoparticle comprises a core comprising a metal.

### Claim 29 (depends on 28)

The composition of claim 28, wherein the metal is Au.

### Claim 30 (depends on 25)

The composition of claim 25, wherein the nanoparticle comprises a shell comprising silica.

### Claim 31 (depends on 30)

The composition of claim 30, wherein the shell has attached, at its surface, PEG ligands.

### Claim 32 (depends on 30)

The composition of claim 30, wherein the shell has attached, at its surface, targeting moieties.

### Claim 33 (depends on 25)

The composition of claim 25, wherein the linker is a DNA molecule.

### Claim 34 (depends on 25)

The composition of claim 25, wherein the therapeutic molecule is doxorubicin.
